LXEO
Lexeo Therapeutics, Inc. Common StockNASDAQHealthcare$5.72+0.87%ClosedMarket Cap: $417.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
12.55
P/S
0.00
EV/EBITDA
0.00
DCF Value
$0.09
FCF Yield
-23.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.3%
ROA
-37.2%
ROIC
0.0%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $86.1M | $-20.9M | $0.06 | — |
| FY 2025 | $0.00 | NaN% | $0.00 | $-100.0M | $-1.86 | — |
| Q3 2025 | $0.00 | -Infinity% | $-21.6M | $-20.3M | $-0.33 | — |
| Q2 2025 | $0.00 | -Infinity% | $-30.7M | $-26.1M | $-0.60 | — |
| Q1 2025 | $0.00 | NaN% | $-33.8M | $-32.7M | $-0.99 | — |
| Q4 2024 | $0.00 | NaN% | $-27.4M | $-25.9M | $-0.78 | — |
| FY 2024 | $0.00 | NaN% | $-105.8M | $-98.3M | $-3.09 | — |
| Q3 2024 | $0.00 | NaN% | $-31.5M | $-29.5M | $-0.89 | — |
| Q2 2024 | $0.00 | NaN% | $-23.6M | $-21.2M | $-0.64 | — |
| Q1 2024 | $0.00 | NaN% | $-23.3M | $-21.7M | $-0.77 | — |
| Q4 2023 | $0.00 | NaN% | $-15.0M | $-14.2M | $-0.52 | — |
| FY 2023 | $0.00 | NaN% | $-68.5M | $-66.4M | $-2.49 | — |